Browsing by Author "Akdis, Mubeccel"

Now showing 1 - 5 of 5

Characterization of b cell responses during checkpoint immunotherapy in metastatic melanoma
(Wiley, 2021-08-01) Fassler, Mirjam; Berner, Fiamma; Akdis, Mubeccel; Flatz, Lukas; Van De Veen, Willem; Cevhertas, Lacin; Bursa Uludağ Üniversitesi/Tıp Fakültesi/İmmunoloji Anabilim Dalı.; 0000-0003-2287-3569; 0000-0003-0554-9943; 0000-0001-9683-8390; KEE-5644-2024
Effect of altered human exposome on the skin and mucosal epithelial barrier integrity
(Taylor & Francis Inc, 2022-10-21) Pat, Yagiz; Oğulur, İsmail; Yazici, Duygu; Mitamura, Yasutaka; Cevhertaş, Laçin; Kucukkase, Ozan C.; Mesisser, Sanne S.; Akdis, Mubeccel; Nadeau, Kari; Akdis, Cezmi A.; Cevhertaş, Laçin; Bursa Uludağ Üniversitesi/Sağlık Bilimleri Enstitüsü/Tıbbi İmmünoloji Anabilim Dalı.; FYD-1431-2022
Pollution in the world and exposure of humans and nature to toxic substances is continuously worsening at a rapid pace. In the last 60 years, human and domestic animal health has been challenged by continuous exposure to toxic substances and pollutants because of uncontrolled growth, modernization, and industrialization. More than 350,000 new chemicals have been introduced to our lives, mostly without any reasonable control of their health effects and toxicity. A plethora of studies show exposure to these harmful substances during this period with their implications on the skin and mucosal epithelial barrier and increasing prevalence of allergic and autoimmune diseases in the context of the "epithelial barrier hypothesis". Exposure to these substances causes an epithelial injury with peri-epithelial inflammation, microbial dysbiosis and bacterial translocation to sub-epithelial areas, and immune response to dysbiotic bacteria. Here, we provide scientific evidence on the altered human exposome and its impact on epithelial barriers.
IL-10 induces IgG4 production in NOD-scid Il2rγnull mice humanized by engraftment of peripheral blood mononuclear cells
(Wiley, 2021-08-07) Cevhertaş, Laçin; Ma, Siyuan; Stanic, Barbara; Ochsner, Urs; Jansen, Kirstin; Ferstl, Ruth; Frei, Remo; Chijoke, Obinna; Munz, Christian; Zhang, Luo; O'Mahony, Liam; Akdis, Mubeccel; van de Veen, Willem; Cevhertaş, Laçin; Bursa Uludağ Üniversitesi/Sağlık Bilimleri Enstitüsü/Tıbbi İmmünoloji Anabilim Dalı.; 0000-0003-2287-3569; EOW-6245-2022
Mechanisms of allergen-specific immunotherapy and allergen tolerance
(Japanese Society of Allergology, 2020-09-06) Küçüksezer, Umut; Özdemir, C.; Öğülür, İ.; Akdis, Mubeccel; Akdis, Cezmi; Cevhertaş, Laçin; Bursa Uludağ Üniversitesi/Tıp Fakültesi/İmmünoloji Anabilim Dalı.; 0000-0003-2287-3569; 57216918051
Allergen-specific immunotherapy (AIT) is the mainstay treatment for the cure of allergic disorders, with depicted efficacy and safety by several trials and meta-analysis. AIT impressively contributes to the management of allergic rhinitis, asthma and venom allergies. Food allergy is a new arena for AIT with promising results, especially via novel administration routes. Cell subsets with regulatory capacities are induced during AIT. IL-10 and transforming growth factor (TGF)-beta are the main suppressor cytokines, in addition to surface molecules such as cytotoxic T-lymphocyte-associated antigen-4 (CTLA-4) and programmed cell death protein-1 (PD-1) within the micro milieu. Modified T- and B-cell responses and antibody isotypes, increased activity thresholds for eosinophils, basophils and mast cells and consequent limitation of inflammatory cascades altogether induce and maintain a state of sustained allergen-specific unresponsiveness. Established tolerance is reflected into the clinical perspectives as improvement of allergy symptoms together with reduced medication requirements and evolved disease severity. Long treatment durations, costs, reduced patient compliance and risk of severe, even life-threatening adverse reactions during treatment stand as major limiting factors for AIT. By development of purified non-allergenic, highly-immunogenic modified allergen extracts, and combinational usage of them with novel adjuvant molecules via new routes may shorten treatment durations and possibly reduce these drawbacks. AIT is the best model for custom-tailored therapy of allergic disorders. Better characterization of disease endotypes, definition of specific biomarkers for diagnosis and therapy follow-up, as well as precision medicine approaches may further contribute to success of AIT in management of allergic disorders.
Regulatory B cells, A to Z
(Wiley, 2021-02-02) Jansen, Kirstin; Cevhertaş, Laçin; Ma, Siyuan; Satitsuksanoa, Pattraporn; Akdis, Mubeccel; van de Veen, Willem; Cevhertaş, Laçin; Bursa Uludağ Üniversitesi/Sağlık Bilimleri Enstitüsü/Tıbbi İmmünoloji Bölümü.; FYD-1431-2022
B cells play a central role in the immune system through the production of antibodies. During the past two decades, it has become increasingly clear that B cells also have the capacity to regulate immune responses through mechanisms that extend beyond antibody production. Several types of human and murine regulatory B cells have been reported that suppress inflammatory responses in autoimmune disease, allergy, infection, transplantation, and cancer. Key suppressive molecules associated with regulatory B-cell function include the cytokines IL-10, IL-35, and TGF-beta as well as cell membrane-bound molecules such as programmed death-ligand 1, CD39, CD73, and aryl hydrocarbon receptor. Regulatory B cells can be induced by a range of different stimuli, including microbial products such as TLR4 or TLR9 ligands, inflammatory cytokines such as IL-6, IL-1 beta, and IFN-alpha, as well as CD40 ligation. This review provides an overview of our current knowledge on regulatory B cells. We discuss different types of regulatory B cells, the mechanisms through which they exert their regulatory functions, factors that lead to induction of regulatory B cells and their role in the alteration of inflammatory responses in different diseases.